Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: The Italian experience and results of its use in daily clinical practice outside clinical trials

Haematologica

Volumn 98, Issue 8, 2013, Pages 1232-1236

  Zinzani, Pier Luigi ^a   Viviani, Simonetta ^b   Anastasia, Antonella ^c   Vitolo, Umberto ^d   Luminari, Stefano ^e   Zaja, Francesco ^f   Corradini, Paolo ^g   Spina, Michele ^h   Brusamolino, Ercole ⁱ   Gianni, Alessandro M ^b   Santoro, Armando ^c   Botto, Barbara ^d   Derenzini, Enrico ^a   Pellegrini, Cinzia ^a   Argnani, Lisa ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

ⁱ FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CHLORPHENIRAMINE; PARACETAMOL;

ADOLESCENT; ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; CHILD; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HODGKIN DISEASE; HUMAN; INCIDENCE; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CHILD; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENERAL PRACTICE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; ITALY; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84880975413     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.083048     Document Type: Article

References (16)

1. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327 (21):1478-84.
2. Diehl V, Franklin J, Pfreundschuh M Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348(7):2386-95.
3. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341(8852): 1051-4.
4. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065-71.
5. Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study. J Clin Oncol. 1999;17 (1):222-9.
6. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011;118(19):5119-25.
7. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(5):320-4.
8. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30(18):2197-03.
9. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-21.
10. Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18(1):248-55.
11. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-9.
12. Cheson BD, Pfistner B, Juwed ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-86.
13. Kaplan ES, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;58:457-81.
14. Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, Jäger U, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood. 2012;120(7):1470-2.
15. Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK Center. Haematologica. 2013;98(4)611-4.
16. Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012; 119(26):6379-81.